Optimapharm Further Expands in the US to Enhance Customer Collaboration
We Deliver on
In line with its strategic growth plans, Optimapharm has opened a new office in Boston, Massachusetts this September. The role of this office will be to further support our current operations in North America and to ensure continued excellence in delivery to our existing and future clients.
“As we continue to expand our mid-market offering, we look forward to joining the life-sciences ecosystem of the very dynamic Boston area! Our investment into the region, supported by our talented team, significantly enhances Optimapharm’s delivery capabilities,” said Ivana Waller, CEO of Optimapharm
Founded in 2006, Optimapharm, with 27 offices in Europe and North America, operates in more than 40 countries. Optimapharm is a mid-market CRO providing full-service solutions and unrivalled access to patients and Investigators, covering markets with a total population of over 900 million people. Optimapharm conducts phase I –IV studies in all therapeutic areas with a specific focus on Oncology, Neurosciences, Cardio-endocrinology-metabolic, and infectious diseases. With very strong operational teams, Optimapharm is also a leading CRO for Medical Device companies and has a reputation for excellence in rescuing studies.
Optimapharm USA Inc. 800 Boylston Street | Prudential Tower, 16th Floor | Boston, Massachusetts | 02199 |
United States of America. email@example.com